Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario A. Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy.
Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.
HPB (Oxford). 2023 Jun;25(6):674-683. doi: 10.1016/j.hpb.2023.02.007. Epub 2023 Feb 24.
Widespread use of minimally invasive liver surgery (MILS) contributed to the reduction of surgical risk of liver resection for hepatocellular carcinoma (HCC). Aim of this study was to analyze outcomes of MILS for single ≤3 cm HCC.
Patients who underwent MILS for single ≤3 cm HCC (November 2014 - December 2019) were identified from the Italian Group of Minimally Invasive Liver Surgery (IGoMILS) Registry.
Of 714 patients included, 641 (93.0%) were Child-Pugh A; 65.7% were limited resections and 2.2% major resections, with a conversion rate of 5.2%. Ninety-day mortality rate was 0.3%. Overall morbidity rate was 22.4% (3.8% major complications). Mean postoperative stay was 5 days. Robotic resection showed longer operative time (p = 0.004) and a higher overall morbidity rate (p < 0.001), with similar major complications (p = 0.431). Child-Pugh B patients showed worse mortality (p = 0.017) and overall morbidity (p = 0.021), and longer postoperative stay (p = 0.005). Five-year overall survival was 79.5%; cirrhosis, satellite micronodules, and microvascular invasion were independently associated with survival.
MILS for ≤3 cm HCC was associated with low morbidity and mortality rates, showing high safety, and supporting the increasing indications for surgical resection in these patients.
微创肝切除术(MILS)的广泛应用降低了肝细胞癌(HCC)肝切除的手术风险。本研究旨在分析 MILS 治疗单个≤3cm HCC 的结果。
从意大利微创肝外科组(IGoMILS)登记处确定了 2014 年 11 月至 2019 年 12 月接受 MILS 治疗单个≤3cm HCC 的患者。
714 例患者中,Child-Pugh A 占 641 例(93.0%);65.7%为局限性切除术,2.2%为广泛切除术,转化率为 5.2%。90 天死亡率为 0.3%。总体发病率为 22.4%(3.8%为严重并发症)。平均术后住院时间为 5 天。机器人切除术的手术时间较长(p = 0.004),总发病率较高(p < 0.001),但严重并发症相似(p = 0.431)。Child-Pugh B 患者的死亡率(p = 0.017)和总发病率(p = 0.021)更高,术后住院时间更长(p = 0.005)。5 年总生存率为 79.5%;肝硬化、卫星微结节和微血管侵犯与生存独立相关。
MILS 治疗≤3cm HCC 的发病率和死亡率低,安全性高,支持对这些患者进行手术切除的适应证不断扩大。